Key Points
- CFO Anshul Maheshwari sold 5,229 shares on January 2 at $19.64 for $102,697.56, leaving him with 180,002 shares (a 2.82% reduction in his stake).
- The CFO has executed multiple insider sales since November, totaling 31,132 shares sold for roughly $610,315, indicating sustained insider selling activity.
- SiBone trades around $20.40 with a market cap of about $885M and a consensus rating of “Moderate Buy” (average target $25); the company recently beat quarterly revenue and EPS estimates but remains unprofitable with negative margins and an expected full-year EPS of -0.78.
SiBone (NASDAQ:SIBN - Get Free Report) CFO Anshul Maheshwari sold 5,229 shares of SiBone stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $19.64, for a total value of $102,697.56. Following the transaction, the chief financial officer directly owned 180,002 shares of the company's stock, valued at approximately $3,535,239.28. The trade was a 2.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Anshul Maheshwari also recently made the following trade(s):
- On Thursday, December 18th, Anshul Maheshwari sold 18,542 shares of SiBone stock. The shares were sold at an average price of $20.15, for a total value of $373,621.30.
- On Tuesday, November 25th, Anshul Maheshwari sold 100 shares of SiBone stock. The stock was sold at an average price of $20.00, for a total transaction of $2,000.00.
- On Friday, November 21st, Anshul Maheshwari sold 1,200 shares of SiBone stock. The stock was sold at an average price of $20.01, for a total value of $24,012.00.
- On Monday, November 17th, Anshul Maheshwari sold 3,460 shares of SiBone stock. The shares were sold at an average price of $17.43, for a total value of $60,307.80.
- On Tuesday, November 11th, Anshul Maheshwari sold 2,601 shares of SiBone stock. The shares were sold at an average price of $18.33, for a total transaction of $47,676.33.
SiBone Price Performance
SIBN opened at $20.40 on Wednesday. SiBone has a 52 week low of $12.49 and a 52 week high of $21.07. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.62 and a current ratio of 7.97. The firm has a market capitalization of $885.16 million, a PE ratio of -40.00 and a beta of 0.69. The company has a fifty day moving average price of $18.58 and a two-hundred day moving average price of $17.04.
SiBone (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. The company had revenue of $48.66 million during the quarter, compared to analyst estimates of $46.67 million. SiBone had a negative net margin of 11.24% and a negative return on equity of 12.86%. As a group, analysts anticipate that SiBone will post -0.78 earnings per share for the current year.
Analyst Ratings Changes
SIBN has been the topic of a number of recent analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of SiBone in a report on Monday, December 29th. Canaccord Genuity Group boosted their price target on SiBone from $26.00 to $27.00 and gave the company a "buy" rating in a research note on Wednesday, December 17th. Morgan Stanley raised their target price on shares of SiBone from $20.00 to $23.00 and gave the company an "overweight" rating in a report on Tuesday, December 2nd. Needham & Company LLC upped their price target on shares of SiBone from $24.00 to $27.00 and gave the stock a "buy" rating in a report on Tuesday, December 16th. Finally, Truist Financial increased their price target on shares of SiBone from $21.00 to $23.00 and gave the stock a "buy" rating in a research report on Thursday, December 18th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, SiBone has a consensus rating of "Moderate Buy" and an average price target of $25.00.
View Our Latest Research Report on SIBN
Institutional Trading of SiBone
A number of hedge funds and other institutional investors have recently bought and sold shares of SIBN. American Century Companies Inc. grew its stake in SiBone by 22.5% in the 3rd quarter. American Century Companies Inc. now owns 2,838,107 shares of the company's stock valued at $41,777,000 after purchasing an additional 521,683 shares during the period. Wellington Management Group LLP raised its position in SiBone by 74.7% in the third quarter. Wellington Management Group LLP now owns 853,266 shares of the company's stock worth $12,560,000 after acquiring an additional 364,897 shares during the period. Peregrine Capital Management LLC purchased a new position in SiBone in the second quarter valued at about $6,664,000. Impax Asset Management Group plc lifted its position in shares of SiBone by 48.2% during the 3rd quarter. Impax Asset Management Group plc now owns 1,025,010 shares of the company's stock valued at $15,088,000 after buying an additional 333,249 shares during the last quarter. Finally, Next Century Growth Investors LLC purchased a new position in SiBone in the 2nd quarter valued at approximately $4,824,000. Institutional investors own 98.11% of the company's stock.
SiBone Company Profile
(
Get Free Report)
Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.
FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
